biologic DMARD
Also written as: DMARD — disease-modifying antirheumatic drug
Advanced disease-modifying medications derived from living organisms, used for refractory pediatric rheumatic diseases.
Full Definition
Biologic disease-modifying antirheumatic drugs (DMARDs) represent a class of targeted therapies derived from living cells or organisms, including monoclonal antibodies and fusion proteins. In pediatric rheumatology, these agents are typically reserved for patients with severe or refractory disease who have failed conventional DMARDs like methotrexate. Common biologics include TNF inhibitors (etanercept, adalimumab), IL-1 blockers (anakinra, canakinumab), and IL-6 inhibitors (tocilizumab). These medications require careful monitoring for infections and other adverse effects, with specific considerations for live vaccine administration in pediatric populations.
Usage
Usage note: Always specify 'biologic' to distinguish from conventional DMARDs in treatment documentation.
In Context
- "The patient was started on biologic DMARD therapy after inadequate response to methotrexate monotherapy." — Treatment escalation note
- "Live vaccines should be avoided in children receiving biologic DMARD treatment due to immunosuppression risks." — Vaccination guideline